Committed to Improving
Outcomes in Cancer

Who We Are

Leapfrog Bio is an emerging oncology therapeutics company leveraging our Precision PGx Platform to identify and develop novel targeted therapeutics.  Our approach utilizes synthetic lethality and pharmacogenomic screening to reveal treatment options for patients suffering from cancer due to “loss of function” mutations.  We are passionate and aligned with our team, board and investors to achieve this important goal.


Board of Directors

Greg Vontz
CEO and Director
Tomas Babak, PhD
CSO and Director
Mike Goguen
Chairman of the Board
J Seth Strattan, PhD
Richard Miller, MD
Independent Director